Leading Chinese Sports Medicine Company WanJie TianYuan Secures Over RMB 100 Million Strategic Investment from Elite Capital, WinX Capital Acts as Exclusive Financial Advisor

VCBeat (WeChat ID: vcbeat) has learned that Beijing Wanjie Medical Device Co., Ltd. (“Wanjie Medical”), a leading domestic sports medicine company, recently secured over RMB 100 million in strategic investment from Elite Capital. This marks another investment move by Elite Capital in China’s sports medicine sector, with WinX Capital serving as the exclusive financial advisor.

In recent years, with the improvement of living standards and fitness awareness among the Chinese population, the number of individuals engaging in sports has increased significantly, leading to a corresponding rise in sports-related injuries. According to data from Global Market Insights, the global sports medicine market size is projected to exceed USD 9 billion in 2025, with an average annual growth rate of nearly 8%, substantially higher than that of traditional orthopedics (2–3%) and orthopedic consumables (5%). In China, the growth of the sports medicine sector is even more rapid. The compound annual growth rate (CAGR) for the industry from 2020 to 2025 is expected to reach 23.4%, the highest among major global markets.

Sports medicine in China is currently embracing a historic opportunity. Although domestic enterprises are still in the early stages of development, they have already acquired the technological capability to compete with foreign companies that dominate the market, and the wave of import substitution is on the horizon.

In this sector, Wanjie Medical engages in the research and development, manufacturing, and sales of high-value consumables in the fields of sports medicine and orthopedic repair. As a national-level high-tech enterprise, it is currently the only company in China to have expanded from sports medicine into the orthopedic repair sector. The company primarily provides orthopedic surgical medical devices and consumables to hospitals at all levels both domestically and internationally. The funds raised in this offering will be primarily used for product research and development in the sports medicine and orthopedic repair industries, as well as to accelerate the commercialization of its products.

As a vice-chairman unit of the China Sports Medicine Innovation Alliance, the company boasts an innovative R&D team led by renowned clinical experts and a master’s and doctoral research team comprising “Outstanding Young Talents.” It has gathered a substantial pool of R&D professionals specializing in polymer biomaterials, tissue engineering, mechanics, and automation. The company has established an interdisciplinary, composite team with core competencies spanning design, materials science, manufacturing, medicine, clinical practice, legal affairs, and marketing.

In April this year, Wanjie Medical successfully obtained two Class III Medical Device Registration Certificates issued by the National Medical Products Administration (NMPA). These certificates cover two core products in the field of sports medicine: ligament fixation screws and suture anchors. The acquisition of these product registration certificates will facilitate the further expansion of the company’s sports medicine product line, enhance its comprehensive competitiveness, and have a positive impact on its future operations. This achievement also further demonstrates Wanjie Medical’s original commitment to becoming a pioneer in specialized orthopedic segments and a leading enterprise in the field of sports medicine.

Mr. Jin Weilun, Founder of Elite CapitalWanjie Medical has cultivated deep expertise in the sports medicine sector, accumulating substantial strengths in both product R&D and sales, and has garnered support from numerous top-tier industry experts in China. The Chinese sports medicine market is on the cusp of explosive growth. Elite Capital’s investment strategy focuses on early positioning before an industry garners widespread market attention. Beyond providing capital, we will assist the company in achieving comprehensive improvements across strategic planning, management and operations, production optimization, and capital operations. We are confident that the company is poised to become the most competitively comprehensive leading enterprise in China’s sports medicine field within three years.

Ms. Zhang Mei, Founder of Wanjie MedicalStated: "We are deeply grateful for the recognition from investors such as Elite Capital. As a trusted partner to entrepreneurs, Elite Capital provides comprehensive support to companies in areas including capital planning, government relations, and key customer acquisition. We also extend our gratitude to our financial advisor, WinX Capital, for their professionalism and dedication."

Dr. Guowen Zou, Founder of WinX CapitalStatement: We are pleased to have served as the exclusive financial advisor to Wanjie Medical, facilitating the introduction of Elite Capital as a strategic investor. The Wanjie Medical team is highly pragmatic, boasting a diverse product portfolio, robust R&D capabilities integrating medicine and engineering, and well-established domestic and international marketing channels. We are confident that Wanjie Medical will continue to lead in the high-growth sports medicine sector.

Elite Capital, established in 2009, is committed to being a dedicated partner behind founders. Aiming to become a private equity investment firm characterized by deep industry cultivation and integration of upstream and downstream industrial chains, Elite Capital focuses on long-term value investment with niche sector investments as its entry point, specifically targeting the biotechnology, medical aesthetics, and medical device industries. Leveraging its profound industry resources and a professional team with extensive investment banking experience, Elite Capital assists enterprises in addressing challenges related to strategic development, market expansion, industrial chain resource integration, financing, mergers and acquisitions, and initial public offerings. This approach drives long-term sustainable growth for enterprises, achieving mutual growth for both the companies and the investment institution.

WinX Capital is a leading investment bank in China’s healthcare sector. Its founding team includes five PhDs in Global Finance from PBC School of Finance, Tsinghua University, while its frontline professionals boast an average of over 10 years of experience in management, investment, and mergers and acquisitions (M&A), with cumulative transaction values exceeding RMB 30 billion. Headquartered in Beijing and Shanghai, WinX Capital serves more than 3,000 active institutional investors and industrial groups. In 2020, it was ranked among the “Top 5 Most Promising New-Type Investment Banks in China” by 36Kr’s WISE Awards, and recognized as one of the “Top 4 Best Financial Advisory Firms in Healthcare” by Qiming Technology & Xinsheng Chuangfu.